Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Camurus ABFRA:7CA +0.54%85 Cyclically Adjusted PB Ratio is 22.27 as of Aug. 09, 2026, which is 24% below its 10-year median of 29.46. GuruFocus rates FRA:7CA with a GF Score™ of 85/100 and a GF Value™ of €61.22 (Fairly Valued). The stock has 1 warning sign investors should review. Among 693 Biotechnology companies, Camurus AB ranks worse than 94.52% on this metric.
The historical rank and industry rank for Camurus AB's Cyclically Adjusted PB Ratio or its related term are showing as below:
FRA:7CA'
s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 17.71 Med: 29.46 Max: 39.78
Current: 21.35
During the past years, Camurus AB's highest Cyclically Adjusted PB Ratio was 39.78. The lowest was 17.71. And the median was 29.46.
FRA:7CA's Cyclically Adjusted PB Ratio is ranked worse than 94.52% of 693
companies
in the Biotechnology industry
Industry Median: 1.62
vs FRA:7CA: 21.35
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.
Camurus AB's adjusted book value per share data for the three months ended in Jun. 2026 was €7.174. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €2.51 for the trailing ten years ended in Jun. 2026.
Shiller PE for Stocks: The True Measure of Stock Valuation
Camurus AB (FRA:7CA) Cyclically Adjusted PB Ratio Explanation
Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.
Camurus AB Cyclically Adjusted PB Ratio Related Terms
Camurus AB Cyclically Adjusted PB Ratio Historical Data
* Premium members only.
The historical data trend for Camurus AB's Cyclically Adjusted PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:7CA vs VRTX, REGN, RVMD: Cyclically Adjusted PB Ratio Comparison
For the Biotechnology subindustry, Camurus AB's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Camurus AB Cyclically Adjusted PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Camurus AB's Cyclically Adjusted PB Ratio distribution charts can be found below:
* The bar in red indicates where Camurus AB's Cyclically Adjusted PB Ratio falls into.
Camurus AB Cyclically Adjusted PB Ratio Calculation
Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.
Camurus AB's Cyclically Adjusted PB Ratio for today is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
What does a Cyclically Adjusted PB Ratio of 22.27 mean?
Camurus AB (FRA:7CA) has a Cyclically Adjusted PB Ratio of 22.27 as of Aug. 09, 2026. Cyclically Adjusted PB Ratio is the ratio of share price to a company's inflation-adjusted book value per share over a 10-year period. View historical data on Camurus AB and its competitors. This is 24% below median its historical median of 29.46. Over the past decade, Camurus AB's Cyclically Adjusted PB Ratio has ranged from 17.71 to 39.78. According to the industry distribution chart, Camurus AB ranks #655 out of 693 companies in the Biotechnology industry, placing it in the top 94.5%.
Is Camurus AB's Cyclically Adjusted PB Ratio too high?
Camurus AB's current Cyclically Adjusted PB Ratio of 22.27 is 24% below median its 10-year median of 29.46. Over the past 10 years, this metric has ranged from a low of 17.71 to a high of 39.78. The Biotechnology industry median Cyclically Adjusted PB Ratio is 1.62. Camurus AB's value of 22.27 is 1274.7% above this industry median. Based on the distribution chart, Camurus AB ranks #655 out of 693 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Camurus AB has a GF Score™ of 85/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Camurus AB's Cyclically Adjusted PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Camurus AB ranks #655 out of 693 companies for Cyclically Adjusted PB Ratio. This places Camurus AB in the lower half of its industry. The industry median Cyclically Adjusted PB Ratio is 1.62. Camurus AB's value of 22.27 is 1274.7% above this benchmark. Historically, Camurus AB's own Cyclically Adjusted PB Ratio has ranged from 17.71 to 39.78 over the past decade. While the company's 10-year median is 29.46 vs. the industry median of 1.62, Camurus AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted PB Ratio for a Biotechnology company?
The median Cyclically Adjusted PB Ratio among Biotechnology companies is 1.62, based on 693 companies in the industry. Companies in the top quartile (top 25%) have a Cyclically Adjusted PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cyclically Adjusted PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Camurus AB's current Cyclically Adjusted PB Ratio of 22.27 is 1274.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted PB Ratio mean?
A high Cyclically Adjusted PB Ratio can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted PB Ratio is the ratio of share price to a company's inflation-adjusted book value per share over a 10-year period. View historical data on Camurus AB and its competitors. For the Biotechnology industry, the median Cyclically Adjusted PB Ratio is 1.62 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Camurus AB's current Cyclically Adjusted PB Ratio is 22.27, which is 24% below median its own 10-year median of 29.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Camurus AB stock overvalued right now?
Based on GuruFocus' analysis, Camurus AB (FRA:7CA) is currently considered Fairly Valued. The stock's GF Value™ is €61.22, compared to a current price of €55.90 — trading 8.7% below its estimated fair value. The current Cyclically Adjusted PB Ratio is 22.27, which is 24% below median its 10-year median of 29.46 and 1274.7% above the Biotechnology industry median of 1.62. Camurus AB's overall GF Score™ is 85/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted PB Ratio calculated?
Cyclically Adjusted PB Ratio is calculated from a company's financial statements. For Camurus AB (FRA:7CA), the current Cyclically Adjusted PB Ratio is 22.27 as of Aug. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Camurus AB (FRA:7CA) Overvalued in 2026?
Based on GuruFocus' analysis, Camurus AB stock appears to be undervalued.
The current stock price of €55.90 is trading 8.7% below its estimated GF Value™ of €61.22.
GuruFocus considers Camurus AB to be Fairly Valued.
Key valuation signals for FRA:7CA:
Cyclically Adjusted PB Ratio: 22.27 (24% below median its 10-year median of 29.46)
GF Value™: €61.22 vs. price of €55.90 (8.7% below fair value)
Industry Position: 1274.7% above the Biotechnology median (#655 of 693)
No single metric tells the full story. See the FRA:7CA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Camurus AB is a science-led biopharmaceutical company focused on developing and commercializing long-acting medicines for the treatment of severe and chronic diseases. It has two approved products, including treatments for opioid dependence, and a development pipeline supported by its FluidCrystal technology. Its clinical pipeline includes product candidates for conditions such as pain, cancer, endocrine, and metabolic diseases, developed in-house and in collaboration with international pharmaceutical companies. Its pipeline programs include CAM2029 for acromegaly, gastroenteropancreatic neuroendocrine tumors, and polycystic liver disease; CAM2038 for chronic pain; CAM4072 for genetic obesity disorders; CAM2043 for Raynaud's phenomenon; CAM4071 for endocrine disorders, among others.
85GF Score
Get the complete analysis for FRA:7CA
Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:7CA has been successfully added to your 
